The purpose of this study was to examine predictors of lymph node (LN) metastases or extrauterine disease (ED) in low-grade (FIGO grade 1 or 2) endometrioid carcinoma (LGEC) in a multi-institutional setting. For LGEC with and without LN metastasis or ED, each of the 9 participating institutions evaluated patients' age, tumor size, myometrial invasion (MI), FIGO grade, % solid component, the presence or absence of papillary architecture, microcystic, elongated, and fragmented glands (MELF), single-cell/cell-cluster invasion (SCI), lymphovascular invasion (LVI), lower uterine segment (LUS) and cervical stromal (CX) involvement, and numbers of pelvic and para-aortic LNs sampled. A total of 304 cases were reviewed: LN + or ED + , 96; LN À /ED À , 208. Patients' ages ranged from 23 to 91 years (median 61 y). Table 1 summarizes the histopathologic variables that were noted for the LN + or ED + group: tumor size Z2 cm, 93/96 (97%); MI > 50%, 54/96 (56%); MELF, 67/96 (70%); SCI, 33/96 (34%); LVI, 79/96 (82%); >20% solid, 65/96 (68%); papillary architecture present, 68/96 (72%); LUS involved, 64/96 (67%); and CX involved, 41/96 (43%). For the LN À /ED À group, the results were as follows: tumor size Z2 cm, 152/208 (73%); MI > 50%, 56/208 (27%); MELF, 79/208 (38%); SCI, 19/208 (9%); LVI, 56/208 (27%); >20% solid, 160/208 (77%); papillary architecture present, 122/208 (59%); LUS involved, 77/208 (37%); CX involved, 24/208 (12%). There was no evidence of a difference in the number of pelvic or para-aortic LNs sampled between groups (P = 0.9 and 0.1, respectively). After multivariate analysis, the depth of MI, CX involvement, LVI, and SCI emerged as significant predictors of advanced-stage disease. Although univariate analysis pointed to LUS involvement, MELF pattern of invasion, and papillary architecture as possible predictors of advanced-stage disease, these were not shown to be significant by multivariate analysis. This study validates MI, CX involvement, and LVI as significant predictors of LN + or ED + . The association of SCI pattern with advanced-stage LGEC is a novel finding.
gynecologic malignancy with approximately 47,000 estimated new cases in 2012. 1 Most of these cases are low-grade, low-stage endometrioid adenocarcinomas. 2, 3 In all, 5% to 18% of clinical stage I, low-grade endometrioid adenocarcinomas may harbor a lymph node metastasis (LNM) or involvement of other extrauterine sites. [4] [5] [6] [7] [8] [9] [10] The low incidence of advanced-stage disease in cases of low-grade endometrioid adenocarcinoma has prompted a debate over the role of LN dissection in this setting [2] [3] [4] 6, 7, 11, 12 and has led to studies seeking to define the subset of patients with low-grade endometrioid adenocarcinoma who could most benefit from surgical staging. [13] [14] [15] Factors that have been traditionally used to predict advanced stage in cases of clinical stage I endometrioid adenocarcinoma include tumor grade and depth of myometrial invasion (MI). 4, 5 In recent years, other factors including tumor size, 14 lower uterine segment (LUS) involvement, 16 cervical involvement, 17 vascular/ lymphatic invasion, 17, 18 revisions to the 3-tiered architectural grading system, 19, 20 and the pattern of MI 21, 22 have been proposed as potential predictive indicators of extrauterine disease (ED). In this study, we assessed the relationship of the above-mentioned predictive factors with the presence of advanced-stage disease in a cohort of 304 cases of low-grade (International Federation of Gynecology and Obstetrics [FIGO] grades 1 and 2) endometrial endometrioid adenocarcinoma.
MATERIALS AND METHODS
This multi-institutional study encompassed cases from 9 tertiary-care centers from 4 countries: Korea, Mexico, Canada, and the United States. Institutional Review Board approval was obtained before the initiation of the study. Each of the 9 participating institutions identified cases of FIGO grade 1 or 2 endometrioid endometrial adenocarcinoma with metastases to the LNs or extrauterine sites at presentation, which were treated by robotic, laparoscopic, or abdominal hysterectomy over a 20-year time span from 1991 to 2011, with available follow-up ranging from 1 to 239 months. All identified cases had histologic material available for review. All FIGO stages were allowed; however, cases with tumor in the ovary, fallopian tube, or peritoneum associated with endometriosis and/or with a uterine tumor lacking myometrial or cervical stromal (CX) invasion were excluded as probable synchronous primaries. One to 2 cases of FIGO grade 1 or 2, stage I or II endometrioid adenocarcinoma with negative LNs were chosen sequentially with each study case and served as the control group. The control group had no evidence of peritoneal disease or adnexal spread at the time of surgery or during follow-up. Using the same criteria as for the study group, cases with synchronous primary endometrioid adenocarcinoma of the ovary, fallopian tube, or peritoneum were excluded. For both the study and control groups, evidence of concomitant serous, clear cell, undifferentiated, or sarcomatous components resulted in exclusion of the case from the study. Clinical and gross pathologic data were obtained from the patients' charts and pathology reports, with age, date of surgery, tumor size, presence/absence of LUS involvement, presence/absence of CX involvement, and number of LNs sampled recorded in each case. Multiple representative cases from each contributing facility were reviewed with the entire group to achieve consensus on how the different variables would be assessed. For cases not reviewed with the entire group, slides were reviewed by at least 2 of the authors.
All cases and controls were reviewed using the standard FIGO grading system 23 cells without obvious keratinization (morular) or polygonal to spindled cells exhibiting obvious keratinization. The percentage of the tumor's solid component was noted, and tumors were then secondarily grouped into those with r20% solid architecture and those with >20% of a solid component. Papillary architecture was defined by the presence of papillary structures with or without a fibroconnective tissue core lined by cells with grade 1 or 2 cytologic atypia. Tumors containing irregular papillae with occasional epithelial buds were included as long as the nuclear grade did not exceed 2. Depth of MI was recorded in all cases as a percentage of the myometrial thickness. Attention was paid to the pattern of MI, specifically whether the microcystic, elongated, and fragmented (MELF) pattern 24 was present. Characteristics of the MELF pattern included the presence of small dilated glands lined by cuboidal or flattened cells with eosinophilic cytoplasm. Invasive glands often had a slitlike appearance. Lining cells could also have a squamoid appearance, and occasional intraluminal tufting of cells was seen. This invasive pattern typically had a myxoid to granulation-like reaction in the surrounding myometrium. Because some group members noted occasional cases in which single cells invaded the myometrium without gland formation or other features identified with the MELF pattern, the presence of single cell or small groups of cells (SCI) as an invasive component in the myometrium was considered separately. SCI was recognized by single cells or groups of eosinophilic cells without formation of a defined structure frequently lying in an edematous or myxoid background. Vascular/lymphatic invasion was defined by the presence of tumor fragments within endothelial-lined vascular/lymphatic spaces either within the tumor or away from it. Efforts were made to exclude possible retraction artifact or possible pseudovascular invasion related to the use of the uterine manipulator in laparoscopic or robotically obtained specimens. Immunohistochemical analysis to demonstrate an endothelial lining in cases of suspected lymphovascular invasion (LVI) was not required.
Univariate and multivariate logistic regression models were used to assess the relationship between pathologic factors and the outcomes of interest. Observations were excluded for unknown tumor size and LNs not sampled. Unknown lower uterine involvement was grouped with no uterine involvement to be consistent with the coding methods for other variables. All statistical analyses were performed using SAS 9.2 for Windows (Copyright r 2011 by SAS Institute Inc., Cary, NC).
RESULTS
A total of 304 patients ranging in age from 23 to 91 years (median, 61 y) were included in the study and were distributed as follows: LNMs with or without ED, 77 (25.3%) patients; ED without LNMs, 19 (6.3%) patients; and no LNMs or ED, 208 (68.4%) patients. For the patients with advanced-stage disease (study group, n = 96), tumor size ranged from 1.5 to 13 cm (mean ± SD 5.0 ± 2.7 cm). For the patients with FIGO stage I/II disease (control group, n = 208), tumor size ranged from 0.2 to 9 cm (mean ± SD 3.5 ± 2.1 cm). Tumor size was unknown for 8 patients. For the 296 patients in whom tumor size was known, 47 (15.9%) had tumors <2.0 cm in greatest dimension. Only 2 such tumors were from patients with advanced-stage disease. One patient had a fallopian tube metastasis, and the other patient had a positive pelvic LN. Sixty-four (67%) study patients had LUS involvement, and in 7 (7%) patients the LUS status was unknown. In the control group, 77 (37%) patients had LUS involvement, and in 34 (16%) patients the LUS status was unknown. Fifty-one study patients had involvement of the cervix: CX stromal invasion, 41 (43%); cervical gland involvement only, 10 (10%). In the control group, 24 (12%) patients had CX stromal invasion. Cervical glandular involvement was noted in 11 (5%) patients. All study and control cases had LN sampling of at least 1 station. There was no significant difference in the total number of pelvic or para-aortic LNs sampled between patients with negative LNs and those with positive LNs (P = 0.09 and 0.10, respectively). Pelvic LNs were sampled in 85 (88.5%) study cases with 1 to 67 pelvic LNs (mean ± SD 13.4 ± 13.1) per patient sampled for a total of 1142 pelvic LNs. Of these, 174 (15%) LNs harbored a metastasis. Fifty (52%) study patients had 1 to 42 (mean ± SD 8.6 ± 9.4) para-aortic LNs sampled for a total of 431 LNs. A metastasis was identified in 66 (15%) of these LNs. Only 2 study patients had positive paraaortic LNs in the setting of histologically proven negative pelvic LNs. Four patients with positive para-aortic LNs did not have sampling of the pelvic LNs. Overall, 66 cases (16 study group, 50 control group) were classified as FIGO grade 1 endometrioid adenocarcinoma, and 238 cases (80 study group; 158 control group) were classified as FIGO grade 2 endometrioid adenocarcinoma. The % solid component of the endometrial tumors ranged from 0% to 45% in both the study and control groups, with 65 (68%) having >20% solid component in the study group and 160 (77%) having >20% solid component in the control group. Papillary architecture was observed at least focally in over half of the cases in the study and control groups: 68 (72%) in the study group and 122 (59%) in the control group. The depth of MI ranged from 0% to 100% in the study group: 0% to 25%, 15 cases; 26% to 50%, 27 cases; 51% to 75%, 20 cases; >75%, 34 cases. One study patient had no MI but had a focus of metastatic carcinoma in the fallopian tube. For the control group, the depth of MI ranged from 0% to 100%: 0% to 25%, 107 cases; 26% to 50%, 44 cases; 51% to 75%, 41 cases; >75%, 16 Preliminary work constructed univariate logistic regression analysis for LNM alone and extrauterine disease alone. In both analyses, LVI and presence of cervical involvement were identified as potential predictors of the outcome modeled (LNM only and extrauterine disease only). Additional variables identified in the analysis looking only at the patients with LNMs identified additional predictive variables including tumor size Z2.0 cm, depth of MI as a continuous variable in 10% increments, presence of >50% MI, presence of papillary architecture, MELF pattern of invasion, SCI, LVI, LUS involvement, CX involvement, and the number of para-aortic LNs sampled. Because the sample size of the cases with extrauterine disease is small, it cannot be determined with certainty whether other variables would become important predictors if more cases were to be added to this group.
When the 2 outcomes are combined into a single univariate logistic regression analysis modeling LNMs or ED, the analysis is very similar to that modeling the outcome of LNM alone pointing to several possible variables predictive of advanced-stage disease in FIGO I/II endometrioid adenocarcinoma including tumor size Z2.0 cm, depth of MI as a continuous variable in 10% increments, presence of >50% MI, presence of papillary architecture, MELF pattern of invasion, SCI, LVI, LUS involvement, CX involvement, and the number of para-aortic LNs sampled. In light of recent changes in the staging of endometrial carcinoma, it is interesting to note that endocervical glandular involvement alone was not found to be a significant predictor of LNM in the univariate model. The results of these univariate analyses modeling LNMs or extrauterine disease are summarized in Table 3 .
DISCUSSION
Partly on the basis of earlier work suggesting that LNMs correlated with other important prognostic factors in endometrial carcinoma, 4 FIGO recommended surgical staging to include sampling of regional LNs over clinical staging alone. 23 Indeed, LNs are among the most common metastatic sites in endometrial carcinoma, yet the incidence of LNMs in patients with FIGO grade 1 or 2 endometrial endometrioid adenocarcinoma is low, ranging from 5% to 18%. [4] [5] [6] [7] [8] [9] [10] Although the benefit of lymphadenectomy in endometrial carcinoma continues to be debated, knowledge of LN status can provide important prognostic information and the opportunity to identify patients requiring adjuvant therapy. The challenge has been to establish how to best identify patients with low-grade endometrioid adenocarcinoma at greatest risk of harboring a LNM in order to avoid overtreatment of the majority of women with this disease. Most studies to date have looked at only 1 to a few risk factors and have been single-institution studies. This multi-institutional study represents the largest contemporary series addressing the issue of predictor factors of advanced-stage disease in cases of lowgrade endometrial endometrioid adenocarcinoma.
Although the univariate analysis confirmed previously reported findings of tumor size Z2 cm, MI > 50%, MELF pattern of invasion, LVI, LUS involvement, and CX stromal invasion as predictors of LNMs, 4, [14] [15] [16] [17] [18] 21 only the percentage of MI, CX stromal invasion, and LVI were found to be independently significantly predictive in the multivariate model. The univariate model also pointed to papillary architecture, SCI pattern of MI, and the number of para-aortic LNs sampled as potential predictors of LNMs. Of these, only SCI was significantly associated with outcome after adjusting for the other factors in the multivariate model. Other variables investigated in the study, including patient age, FIGO grade 1 versus 2, the percentage of solid architecture, and the number of pelvic LNs obtained, were not found to be significant predictors of advanced-stage disease in the univariate models, although the percentage of solid architecture approached significance (P = 0.0527).
Little has been written about the association of age with advanced-stage disease. Older series have pointed to increased age as a risk factor for poor outcome, 24, 25 but these studies did not address the relationship of age with the presence of advanced-stage disease. A recent study assessing nodal metastasis risk utilizing triage criteria proposed by the Mayo Clinic 14 found no significant age difference between patients with and without LNMs. The present study is in agreement and supports exclusion of age as a factor in the decision whether or not to surgically stage a patient.
The tumor grade in endometrial endometrioid adenocarcinoma is typically included with staging information, because grade correlates with surgical stage and ultimately prognosis, 4, 5, 19 with the impact most apparent in grade 3 tumors. Later studies have grouped FIGO grade 1 and 2 tumors as a "low-grade" entity in order to stratify risk with respect to LNMs, 14,26 and 1 study showed no survival differences between grade 1 and grade 2 endometrial tumors. 27 Furthermore, it has been shown that binary grading systems have improved interobserver and intraobserver agreement. 19, 20 This study specifically excluded grade 3 endometrioid adenocarcinoma to determine whether a group with increased risk for advanced-stage disease could be identified within what is conceptualized as a low-risk category overall. This study found no difference in the risk for LNMs or ED between FIGO grade 1 and 2 tumors. However, FIGO grade 2 tumors represent the majority of cases in this study begging the question whether a FIGO grade 2 tumor with a lower percentage of solid nonsquamous ar-chitecture would have less risk for LNMs than a tumor with a percentage of solid, nonsquamous architecture approaching 50%. One group of investigators tested this approach using a 20% threshold and found that this threshold was exceeded in all patients who recurred. 19 Although this study did not find increased odds of advanced-stage disease in tumors with >20% solid architecture, the absence of difference between grades 1 and 2 in the current grading system in combination with previously published work suggests that a revision from a 3-tier to a 2-tier grading system should be seriously considered.
Debating the role of LN dissection in cases of lowgrade endometrial endometrioid adenocarcinoma is beyond the scope of this study, but intuitively it seems that increased numbers of LNs sampled should lead to increased detection of LNMs. To that end, some have proposed a target number of LNs to be sampled for optimal detection, 28 and 1 study reported that the number of pelvic LNs sampled was a factor increasing the detection of LNMs. 6 A later study demonstrated that the absolute LN count did not accurately predict the presence of LNMs. 8 To address whether patients with LNMs were identified on the basis of the increased number of LNs sampled, we compared sampling of pelvic and para-aortic LNs between the study and control groups. No significant differences in the number of pelvic or para-aortic LNs sampled between low-stage and advanced-stage groups (P = 0.10 and 0.64, respectively) were identified. Although the univariate model did show increased odds of the presence of a LNM with increasing number of paraaortic LNs sampled, this finding was not true for the number of pelvic LNs sampled. Between the study and control patient groups there were too many missing values for numbers of LNs, because not every patient underwent both pelvic and para-aortic LN dissections. For this reason, as well as the absence of significance for number of pelvic LNs, these variables were excluded from the multivariate analysis. Variability with respect to individual patients and surgeons may limit the ability to ultimately assess whether an "adequate" LN dissection with no evidence of metastatic carcinoma is reassuring. The univariate model pointed to both traditional and nontraditional features as potential predictors of advanced-stage disease, some of which could not be confirmed as independent variables on the multivariate analysis. One such variable that has recently been given attention due to its utilization as part of a staging protocol 14 is tumor size Z2.0 cm. Although a greater percentage of patients in the study group had tumors Z2.0 cm compared with that in the control group, it should be noted that for both groups, tumor size <2.0 cm was relatively uncommon. Overall, only 47 patients had tumors <2.0 cm in size. Of these, 2 (2.1%) were patients with advanced-stage disease, and 1 of these patients had >50% MI. As the criterion of <50% MI was not met, this patient would have been staged under the Mayo protocol. This suggests that tumor size did not add any information that could not be provided by another variable. Although this variable may be useful in combination with others, this study does not support tumor size as the sole determinant in deciding whether or not to proceed with staging.
Another proposed predictor of LNMs not supported by multivariate analysis in this study is the presence of LUS involvement. One study including all grades and histotypes of endometrial adenocarcinoma found LUS involvement to be significantly associated with LNMs on multivariate analysis in patients with endometrioid histology. 16 The number of patients in this study that also had endocervical involvement was not reported. Significantly, our study could not confirm the association of LUS involvement with advanced-stage disease by multivariate analysis when CX involvement was included in the model. A closer look at our raw data shows that 40/ 64 (62.5%) study patients with LUS involvement also had either endocervical gland (9/24) or stromal involvement (31/64), whereas 24/77 (31%) control patients with documented LUS involvement had either endocervical gland or stromal involvement. This suggests that the presence of LUS involvement could be an indicator of possible endocervical involvement rather than a significant predictor of advanced-stage disease.
One potential predictor of LNMs not included in the multivariate analysis was the presence of papillary architecture. The largest paper on this subject reported that the prognosis of endometrioid adenocarcinoma with papillary or villoglandular architecture was similar to endometrioid adenocarcinoma with glandular architecture. 29 However, other investigators suggested that the incidence of LVI and LNMs was higher when a villoglandular pattern was observed in the myoinvasive component of a low-grade endometrial endometrioid adenocarcinoma, 30 and unpublished observations of 1 group member are in concordance with the latter opinion. Our study examined only the presence or absence of papillary architecture and did not specifically address papillary architecture in the myoinvasive component. In reviewing the slides for this study, there was some variability between group members with respect to what constituted papillary architecture and whether intraglandular papillary formation should be included. In addition, it appeared that papillary architecture correlated with the percent of MI. Because the percentage of MI was more easily reproduced and was established in the literature as a predictor, this variable was chosen for inclusion in the multivariate model over papillary architecture. The finding that this architectural pattern could be a predictor of more aggressive behavior on the univariate analysis requires further study to determine the relationship of papillary architecture with advanced-stage disease and, potentially, outcome.
Of the significant predictors of LNM or ED identified on multivariate analysis, MI, CX stromal invasion, and LVI are factors used to guide clinical management evidenced by their inclusion on national and international cancer-reporting checklists. 31 In addition, MI and CX stromal invasion establish the FIGO stage of the patient. 32 Most studies of CX involvement and LVI relate these features to outcome and recurrence, with relatively few studies relating these features specifically to the odds of LNMs or extrauterine disease. Two studies that included all grades of endometrial carcinoma found that both LVI and CX involvement are independent prognostic factors for LNMs. 17, 33 Our study confirms these findings even with the exclusion of high-grade adenocarcinoma. In a real-time setting such as a frozen section, the utility of LVI or CX stromal invasion is yet to be determined. Until that time, it would be reasonable to submit a section of cervix if there is suspicion of involvement and to report vascular invasion if it is observed at the time of intraoperative evaluation. Postsurgery, these features could be useful in determining the need for adjuvant therapy in the unstaged patient. More has been written about the relationship of deep MI with the odds of advanced-stage disease. 4, 5, [14] [15] [16] Although the odds are greatest in the setting of high-grade endometrioid adenocarcinoma (FIGO grade 3) and outer MI, deeply invasive FIGO grade 2 endometrioid adenocarcinoma remains predictive of pelvic and para-aortic LNMs in 19% and 14% of patients, respectively. 5 This study specifically excluded FIGO grade 3 endometrioid and nonendometrioid adenocarcinoma, which confirms and underscores the significance of MI even within the context of so-called low-grade endometrioid adenocarcinoma. This is important as MI is a parameter that can be assessed intraoperatively and can guide the decision whether to perform staging. Although earlier studies question the reliability of intraoperative assessment of MI, 34 recent studies have shown high frozen/permanent section concordance with respect to MI. 35, 36 After publication of the Gynecologic Oncology Group study demonstrating the relationship of MI with ED, 5 2 studies demonstrated a relationship between a diffuse pattern of MI and worse patient outcome. 25, 37 Although not fully characterized in either study, both noted unusual features in some infiltrating glands including a mixed inflammatory response in the myoinvasive component 37 and some glands with flattened epithelium mimicking endothelial cells. 25 Both studies provide images bearing a striking resemblance to a distinct myoinvasive pattern subsequently characterized by Marshall et al 38 and Murray et al. 39 Marshall and colleagues reported in a 2003 abstract the existence of a myoinvasive subtype composed of attenuated epithelium and single cells, which was frequently associated with LVI. Murray and colleagues further observed that glands with these features frequently evoke a prominent fibromyxoid stromal reaction and coined the acronym MELF to describe the findings in the glandular component. This study suggested that the glandular changes were possibly of a degenerative nature but that when accompanied by an associated fibromyxoid stromal response it was associated with LVI and a worse longterm prognosis. Stewart et al 40 confirmed the association of MELF pattern with LVI and observed that the pattern was typically associated with FIGO grade 1 or 2 endometrioid adenocarcinoma usually present along the deepest point of invasion. In contrast to Murray and colleagues, this study proposed that the changes observed in the MELF pattern represent a tumor/stromal response. Stewart and Little 41 subsequently observed that tumors with MELF-type invasion had reduced hormone receptor and E-cadherin expression compared with areas of conventional-type invasion within the same tumor, features that are shared by epithelialmesenchymal transition in carcinomas at other sites. The changes associated with epithelial-mesenchymal transition reportedly allow infiltration into the surrounding stroma and could potentiate tumor progression.
On the basis of these studies and others linking the pattern of MI to patient outcome, this variable was included in the present study, which focused on the presence of advanced-stage disease rather than patient outcome. Modeled after 1 study, 22 patterns of MI such as groups of glands and single glands in addition to the MELF pattern were included in the initial case analysis. During the course of the study, consensus on the distinction of small gland groups from single glands and the percentage of each pattern could not be reached in all cases. Therefore, these categories were abandoned in favor of focusing solely on MELF and a second, SCI pattern, both of which were readily identified by all members because of the prominent stromal response typically associated with these patterns. Although previous studies have included SCI within the spectrum of MELF-associated changes, 21, 22, 39, 40 the decision to separate the patterns was based on some members of our group observing SCI outside the context of MELF. Because not all slides were available in every case and the number of foci per slide was difficult to quantify, only the presence or absence of MELF or SCI was noted. The overall incidence of MELF in our study was 48%. This is higher than the reported frequency of MELF, which ranges from 7% to 44%. 21, 22, 39, 40 The higher frequency in our study could be, in part, because of a nonconsecutive review. The study was limited to patients who had undergone LN sampling potentially leading to a bias toward cases perceived to be more aggressive preoperatively. Although the amount of MELF was not quantified, it was noted to comprise Z50% of the myoinvasive component in 58/146 cases that had MELF. However, similar to the findings by Stewart et al, 40 we observed that MELF could be focal. As cases with focal and widespread MELF were combined into a single category, it is possible that this also contributed to our observation of this finding in a higher percentage of cases. In most cases, in agreement with Stewart and colleagues, MELF was observed along the leading aspect of invasion. Overall, 52 (17%) cases in this study had SCI. There appears to be a relationship between MELF and SCI. The majority of cases with SCI also had MELF (41/ 52, 78.8%), although the converse was not true; the majority of cases with MELF (105/146, 71.9%) did not have SCI. It is possible that SCI could represent an evolving, more aggressive, variant of MELF. However, there were 11 cases in which SCI was seen without MELF, raising the possibility that this pattern could also develop outside the spectrum of MELF, although a sampling issue cannot be excluded. In the univariate model, both SCI and MELF were predictive of the odds of an LNM or ED, but only SCI was an independent predictor of advanced-stage disease on the multivariate analysis. Combining both patterns into a single category did not bring the MELF pattern to significance in keeping with the findings of Murray et al. 39 In contradistinction, only 1 study, which included SCI within the spectrum of MELF, 21 found the MELF pattern to be predictive of LNMs. The authors note a high rate of LVI in cases with MELF, but no multivariate analysis was undertaken to determine whether MELF was an independent prognostic variable. Regardless of whether SCI is part of the MELF spectrum, its presence should be regarded as possibly predictive of LNM. The idea that the pattern of MI could be associated with advanced-stage disease is novel, and our study supports that SCI, previously included in the spectrum of MELF, increases the odds of advanced-stage disease.
In summary, this multi-institutional study validates other studies' findings that MI, LVI, and CX stromal invasion are independent risk factors for LNMs or extrauterine disease. Of these variables, MI is the most readily evaluated intraoperatively. The presence of SCI pattern as a predictor of advanced-stage disease is a novel finding. This pattern is typically associated with MELF, and MELF could be a marker for both SCI and LVI. SCI is most likely to be identified in permanent sections. When identified, extra care should be taken when evaluating LNMs, as metastases associated with SCI may also be composed only of single cells 21 (Fig. 2) . Additional study is required to determine whether SCI has clinical applications and should be considered as an additional risk factor when evaluating the need for adjuvant therapy in the unstaged patient.
